Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

White Paper on Sugammadex API

White Paper on Sugammadex API

Sugammadex is a medication used to reverse the effects of certain muscle-relaxing drugs (rocuronium and vecuronium) during anaesthesia. It works by forming a complex with these drugs, neutralizing their effects, and restoring muscle function, allowing for a rapid reversal of muscle relaxation. Sugammadex works by forming a complex with muscle-relaxing drugs (rocuronium and vecuronium), neutralizing their effects. This complex helps rapidly reverse muscle relaxation, restoring muscle function.

Sugammadex sodium is one of the key molecules in Dr. Reddy’s API portfolio and an ideal use case on how a thorough understanding of the interaction between API and formulation can significantly improve the robustness of the formulation process considering the drug substance’s proneness to degradation in the formulation process.

Our development approach:

We adopted QbD (Quality by Design) and an integrated drug developmental approach, looking not only at the API but also studying the formulation. The QTPP (Quality Target Product Prole) of the API was determined considering the drug substance’s proneness to degradation in the formulation process, especially during the terminal sterilisation (TS) process for intravenous injection.

To know more about our API offerings, please read the White paper on Sugammadex Sodium API by filling the contact form below.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.



Book your slot to
explore our API solutions firsthand!

Schedule a meeting at CPHI China